Emergent BioSolutions (EBS) Revenue & Revenue Breakdown


OverviewForecastOwnershipFinancialsChartTranscripts

Emergent BioSolutions Revenue Highlights


Latest Revenue (Y)

$1.05B

Latest Revenue (Q)

$254.70M

Main Segment (Y)

Product

Main Geography (Y)

Services Segment

Emergent BioSolutions Revenue by Period


Emergent BioSolutions Revenue by Year

DateRevenueChange
2023-12-31$1.05B-6.39%
2022-12-31$1.12B-37.47%
2021-12-31$1.79B15.26%
2020-12-31$1.56B40.63%
2019-12-31$1.11B41.36%
2018-12-31$782.40M39.50%
2017-12-31$560.87M14.75%
2016-12-31$488.78M-6.50%
2015-12-31$522.79M16.14%
2014-12-31$450.14M43.93%
2013-12-31$312.75M10.95%
2012-12-31$281.89M3.11%
2011-12-31$273.38M-4.47%
2010-12-31$286.17M21.89%
2009-12-31$234.79M31.49%
2008-12-31$178.55M-2.38%
2007-12-31$182.91M19.76%
2006-12-31$152.73M16.87%
2005-12-31$130.69M56.52%
2004-12-31$83.49M49.71%
2003-12-31$55.77M-28.99%
2002-12-31$78.54M73.35%
2001-12-31$45.31M-

Emergent BioSolutions generated $1.05B in revenue during NA 2023, up -6.39% compared to the previous quarter, and up 134.11% compared to the same period a year ago.

Emergent BioSolutions Revenue by Quarter

DateRevenueChange
2024-06-30$254.70M-15.21%
2024-03-31$300.40M8.60%
2023-12-31$276.60M2.26%
2023-09-30$270.50M-19.95%
2023-06-30$337.90M104.66%
2023-03-31$165.10M-50.08%
2022-12-31$330.70M37.79%
2022-09-30$240.00M-1.11%
2022-06-30$242.70M-21.07%
2022-03-31$307.50M-57.48%
2021-12-31$723.20M119.82%
2021-09-30$329.00M-17.23%
2021-06-30$397.50M15.89%
2021-03-31$343.00M-41.17%
2020-12-31$583.00M51.35%
2020-09-30$385.20M-2.41%
2020-06-30$394.70M105.04%
2020-03-31$192.50M-46.59%
2019-12-31$360.40M15.59%
2019-09-30$311.80M28.21%
2019-06-30$243.20M27.60%
2019-03-31$190.60M-29.59%
2018-12-31$270.70M55.89%
2018-09-30$173.65M-21.14%
2018-06-30$220.20M86.90%
2018-03-31$117.81M-39.21%
2017-12-31$193.81M29.70%
2017-09-30$149.43M48.29%
2017-06-30$100.77M-13.77%
2017-03-31$116.86M-22.95%
2016-12-31$151.66M6.12%
2016-09-30$142.91M40.82%
2016-06-30$101.49M-8.57%
2016-03-31$111.00M-33.97%
2015-12-31$168.10M1.92%
2015-09-30$164.94M30.79%
2015-06-30$126.11M98.19%
2015-03-31$63.63M-57.00%
2014-12-31$147.97M7.26%
2014-09-30$137.95M25.04%
2014-06-30$110.33M104.75%
2014-03-31$53.88M-45.08%
2013-12-31$98.11M10.11%
2013-09-30$89.10M8.09%
2013-06-30$82.44M91.27%
2013-03-31$43.10M-54.44%
2012-12-31$94.61M42.07%
2012-09-30$66.59M-5.38%
2012-06-30$70.38M39.89%
2012-03-31$50.31M-53.39%
2011-12-31$107.95M83.70%
2011-09-30$58.76M-33.33%
2011-06-30$88.14M375.59%
2011-03-31$18.53M-82.05%
2010-12-31$103.25M39.55%
2010-09-30$73.99M19.07%
2010-06-30$62.14M32.77%
2010-03-31$46.80M-13.02%
2009-12-31$53.80M24.34%
2009-09-30$43.27M-40.88%
2009-06-30$73.19M13.44%
2009-03-31$64.52M80.47%
2008-12-31$35.75M-36.84%
2008-09-30$56.60M30.16%
2008-06-30$43.48M1.79%
2008-03-31$42.72M-52.34%
2007-12-31$89.64M-

Emergent BioSolutions generated $254.70M in revenue during Q2 2024, up -15.21% compared to the previous quarter, and up 154.27% compared to the same period a year ago.

Emergent BioSolutions Revenue Breakdown


Emergent BioSolutions Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Commercial Product$497.30M----
Product$944.50M$966.20M---
Contracts and Grants$26.30M$41.40M$71.30M--
Service$72.80M----
Contract Development And Manufacturing-$113.30M$450.50M$80.00M-
Contract Development And Manufacturing, Leases--$108.00M--
Contracted Operating Leases---$165.30M-

Emergent BioSolutions's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (61.30%), Commercial Product (32.27%), Service (4.72%), and Contracts and Grants (1.71%).

Quarterly Revenue by Product

Product/ServiceSep 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Sep 20
Contracts and Grants$10.00M$6.70M$6.50M$6.60M$6.50M$7.10M$17.40M$7.30M$9.60M----
Service$13.90M$59.60M$13.20M--$17.70M-------
Product$269.50M$249.10M$249.80M$302.20M$143.40M$305.70M-------
Commercial Product$95.30M------------
Contract Development And Manufacturing--$14.20M$29.10M$15.20M$17.90M-------
Contract Development And Manufacturing, Leases------$200.00K$400.00K$104.20M$114.60M---
Contracted Operating Leases----------$129.70M$146.60M$177.70M

Emergent BioSolutions's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (69.33%), Commercial Product (24.52%), Service (3.58%), and Contracts and Grants (2.57%).

Emergent BioSolutions Revenue Breakdown by Country

Annual Revenue by Country

CountryDec 23Dec 22Dec 21Dec 20Dec 19
Services Segment$78.50M----
CANADA-$148.60M---
UNITED STATES-$889.50M$897.80M$626.00M$568.80M
Other Geographical Area-$82.80M---
Non-US--$894.90M$363.80M$334.70M

Emergent BioSolutions's latest annual revenue breakdown by geography, as of Dec 23: Services Segment (100.00%).

Quarterly Revenue by Country

CountrySep 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Services Segment$14.30M$20.00M$14.20M$29.10M$15.20M---------------
UNITED STATES-----$602.80M$49.80M$124.40M$112.50M$502.60M$60.20M$66.30M$56.40M$235.50M$102.40M$224.20M$63.90M$230.70M$170.20M$94.60M
Non-US------$190.20M$118.30M$195.00M$220.60M$268.80M$114.90M$81.50M$105.40M$99.80M$74.30M$84.30M$80.10M$86.00M$88.90M

Emergent BioSolutions's latest quarterly revenue breakdown by geography, as of Sep 24: Services Segment (100.00%).

Emergent BioSolutions Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
BHCBausch Health Companies$8.76B$2.51B
ZTSZoetis$8.54B$2.39B
NBIXNeurocrine Biosciences$1.89B$622.10M
ALKSAlkermes$1.66B$378.14M
PBHPrestige Consumer Healthcare$1.13B$283.55M
EBSEmergent BioSolutions$1.05B$254.70M
COLLCollegium Pharmaceutical$566.77M$159.30M
ITCIIntra-Cellular Therapies$462.18M$175.38M
DCPHDeciphera Pharmaceuticals$163.36M$45.00M
LFCRLifecore Biomedical$128.26M$24.70M
CPIXCumberland Pharmaceuticals$39.55M$9.09M
DRRXDURECT$8.55M$1.56M
AKANAkanda$2.16M$762.61K
PETQPetIQ$1.10M$328.94M

EBS Revenue FAQ


What is Emergent BioSolutions’s yearly revenue?

Emergent BioSolutions's yearly revenue for 2023 was $1.05B, representing a decrease of -6.39% compared to 2022. The company's yearly revenue for 2022 was $1.12B, representing a decrease of -37.47% compared to 2021. EBS's yearly revenue for 2021 was $1.79B, representing an increase of 15.26% compared to 2020.

What is Emergent BioSolutions’s quarterly revenue?

Emergent BioSolutions's quarterly revenue for Q2 2024 was $254.7M, a -15.21% decrease from the previous quarter (Q1 2024), and a -24.62% decrease year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $300.4M, a 8.60% increase from the previous quarter (Q4 2023), and a 81.95% increase year-over-year (Q1 2023). EBS's quarterly revenue for Q4 2023 was $276.6M, a 2.26% increase from the previous quarter (Q3 2023), and a -16.36% decrease year-over-year (Q4 2022).

What is Emergent BioSolutions’s revenue growth rate?

Emergent BioSolutions's revenue growth rate for the last 3 years (2021-2023) was -41.47%, and for the last 5 years (2019-2023) was -5.13%.

What are Emergent BioSolutions’s revenue streams?

Emergent BioSolutions's revenue streams in c 23 are Commercial Product, Product, Contracts and Grants, and Service. Commercial Product generated $497.3M in revenue, accounting 32.27% of the company's total revenue Product generated $944.5M in revenue, accounting 61.30% of the company's total revenue, down -2.25% year-over-year. Contracts and Grants generated $26.3M in revenue, accounting 1.71% of the company's total revenue, down -36.47% year-over-year. Service generated $72.8M in revenue, accounting 4.72% of the company's total revenue

What is Emergent BioSolutions’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Emergent BioSolutions was Product. This segment made a revenue of $944.5M, representing 61.30% of the company's total revenue.